ABCL Stock Summary and Trading Ideas (Abcellera Biologics - Common Shares | NASDAQ:ABCL)

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.

As of February 3, 2023, ABCL stock price climbed to $11.18 with 1,032,905 million shares trading.

ABCL has a beta of 0.94, meaning it tends to be less sensitive to market movements. ABCL has a correlation of 0.12 to the broad based SPY ETF.

ABCL has a market cap of $3.20 billion. This is considered a Mid Cap stock.

Last quarter Abcellera Biologics - Common Shares reported $101 million in Revenue and $.08 earnings per share. This beat revenue expectation by $26 million and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IWM, IBB, IWN, AVUV, IWO.

ABCL has outperformed the market in the last year with a price return of +19.7% while the SPY ETF lost -6.3%. However, in the short term, ABCL had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.7% vs +11.6% return in SPY. But in the last 2 weeks, ABCL shares have fared better than the market returning +8.1% compared to SPY +4.2%.

ABCL support price is $10.69 and resistance is $11.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL stock will trade within this expected range on the day.